{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T22:14:33Z","timestamp":1790460873519,"version":"4.1.0"},"reference-count":39,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"unspecified","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["P-2017-08-ST2-014"],"award-info":[{"award-number":["P-2017-08-ST2-014"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2024,8,16]]},"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Health research bodies recommend patient involvement and engagement in research and healthcare planning, although their implementation is not yet widespread. This deficiency extends to progressive pulmonary fibrosis (PPF), where crucial aspects remain unknown, including causal mechanisms, curative treatments and optimal symptom management. This study addresses these gaps by seeking stakeholders\u2019 perspectives to guide research and treatment directions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Method<\/jats:title>\n                  <jats:p>A priority-setting partnership was established to explore stakeholders\u2019 priorities in the diagnosis, treatment, management and care of PPF, including idiopathic pulmonary fibrosis which is the archetypal PPF. Stakeholders included people living with PPF, their carers, relatives and healthcare professionals involved in their management.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Through an online open-ended survey, 2542 responses were collected from 638 stakeholders. Thematic analysis identified 48 specific research questions, which were then cross-referenced with academic literature to pinpoint research gaps. Following the evidence check, 44 unanswered questions were shortlisted by 834 stakeholders in a second online survey. Ultimately, a top 10 priority list was established through consensus.<\/jats:p>\n                  <jats:p>The prioritised research questions include (1) improved diagnosis accuracy and timing, (2) development of new treatments, (3) enhanced accuracy in primary care, (4) optimal timing for drug and non-drug interventions, (5) effective cough treatment, (6) early intervention for PPF, (7) improved survival rates, (8) symptom reduction, (9) impact of interventions on life expectancy and (10) new treatments with reduced side effects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Stakeholders\u2019 priorities can be summarised into five areas: early diagnosis, drug and non-drug treatments, survival and symptom management. Ideally, these topics should guide funding bodies and health policies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjresp-2024-002368","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T01:15:46Z","timestamp":1725412546000},"page":"e002368","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":14,"title":["Research priorities for progressive pulmonary fibrosis in the UK"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8250-6464","authenticated-orcid":false,"given":"Laura","family":"Fabbri","sequence":"first","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London Department of Medicine, London, UK"},{"name":"Department of Respiratory Medicine, Royal Brompton Hospital, London, UK"},{"name":"Nottingham Biomedical Research Centre, National Institute for Health Research, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Russell","sequence":"additional","affiliation":[{"name":"College of Medical and Dental Sciences (MDS) University of Birmingham, Birmingham, UK"},{"name":"University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazia","family":"Chaudhuri","sequence":"additional","affiliation":[{"name":"University of Ulster Faculty of Life and Health Sciences, Londonderry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Adams","sequence":"additional","affiliation":[{"name":"Action for Pulmonary Fibrosis, Peterborough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Cowan","sequence":"additional","affiliation":[{"name":"James Lind Alliance, Southampton, UK"},{"name":"Katherine Cowan Consulting Limited, East Sussex, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Conway","sequence":"additional","affiliation":[{"name":"Patient Representative, Tooting, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Dickinson","sequence":"additional","affiliation":[{"name":"Carer Representative, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gibbons","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, Royal Devon & Exeter NHS Foundation Trust, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Hart","sequence":"additional","affiliation":[{"name":"Respiratory Research Group, Hull York Medical School\/University of Hull, Cottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Jones","sequence":"additional","affiliation":[{"name":"Action for Pulmonary Fibrosis, Peterborough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Lynch-Wilson","sequence":"additional","affiliation":[{"name":"Hywel Dda University Health Board, Carmarthen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"McMillan","sequence":"additional","affiliation":[{"name":"Carer Representative, Ballycastle, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Milward","sequence":"additional","affiliation":[{"name":"Patient Representative, Bolton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Ward","sequence":"additional","affiliation":[{"name":"Carer Representative, Tameside, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise Elisabeth","family":"Wright","sequence":"additional","affiliation":[{"name":"Action for Pulmonary Fibrosis, Peterborough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7929-2119","authenticated-orcid":false,"given":"Gisli","family":"Jenkins","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London Department of Medicine, London, UK"},{"name":"Department of Respiratory Medicine, Royal Brompton Hospital, London, UK"},{"name":"Nottingham Biomedical Research Centre, National Institute for Health Research, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,9,3]]},"reference":[{"key":"2025083110035431000_11.1.e002368.1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-216616"},{"key":"2025083110035431000_11.1.e002368.2","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-017124","article-title":"Reviewing progress in public involvement in NIHR research: developing and implementing a new vision for the future","volume":"8","author":"Staniszewska","year":"2018","journal-title":"BMJ Open"},{"key":"2025083110035431000_11.1.e002368.3","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph17051741","article-title":"The Mediating Role of the Patient Health Engagement Model on the Relationship Between Patient Perceived Autonomy Supportive Healthcare Climate and Health Literacy Skills","volume":"17","author":"Barello","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"2025083110035431000_11.1.e002368.4","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-020-05912-0"},{"key":"2025083110035431000_11.1.e002368.5","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02718-2020","article-title":"Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study)","volume":"57","author":"Nasser","year":"2021","journal-title":"Eur Respir J"},{"key":"2025083110035431000_11.1.e002368.6","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202202-0399ST"},{"key":"2025083110035431000_11.1.e002368.7","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03187-2021","article-title":"Progressive pulmonary fibrosis: an expert group consensus statement","volume":"61","author":"Rajan","year":"2023","journal-title":"Eur Respir J"},{"key":"2025083110035431000_11.1.e002368.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2005230"},{"key":"2025083110035431000_11.1.e002368.9","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01204-2015"},{"key":"2025083110035431000_11.1.e002368.10","doi-asserted-by":"crossref","unstructured":"Moor CC , Wijsenbeek MS , Balestro E , et al . Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey. ERJ Open Res 2019;5. doi:10.1183\/23120541.00124-2019","DOI":"10.1183\/23120541.00124-2019"},{"key":"2025083110035431000_11.1.e002368.11","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-207439"},{"key":"2025083110035431000_11.1.e002368.12","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-215917"},{"key":"2025083110035431000_11.1.e002368.13","unstructured":"The James Lind Alliance guidebook version 10. 2021. Available: https:\/\/www.jla.nihr.ac.uk\/jla-guidebook\/downloads\/JLA-Guidebook-Version-10-March-2021.pdf [Accessed 04 Sep 2023]."},{"key":"2025083110035431000_11.1.e002368.14","unstructured":"Survey monkey. 2022. Available: https:\/\/www.surveymonkey.co.uk"},{"key":"2025083110035431000_11.1.e002368.15","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-019-0889-3","article-title":"Reporting guideline for priority setting of health research (REPRISE)","volume":"19","author":"Tong","year":"2019","journal-title":"BMC Med Res Methodol"},{"key":"2025083110035431000_11.1.e002368.16","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-215731"},{"key":"2025083110035431000_11.1.e002368.17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0297832","article-title":"A scoping review of the unmet needs of patients diagnosed with idiopathic pulmonary fibrosis (IPF)","volume":"19","author":"Bramhill","year":"2024","journal-title":"PLoS One"},{"key":"2025083110035431000_11.1.e002368.18","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1164\/rccm.202205-0910LE","article-title":"Patient Characteristics and Survival for Progressive Pulmonary Fibrosis Using Different Definitions","volume":"207","author":"Khor","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2025083110035431000_11.1.e002368.19","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-019-1076-0","article-title":"Risk factors for diagnostic delay in idiopathic pulmonary fibrosis","volume":"20","author":"Hoyer","year":"2019","journal-title":"Respir Res"},{"key":"2025083110035431000_11.1.e002368.20","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.711194","article-title":"Patient Reported Experiences and Delays During the Diagnostic Pathway for Pulmonary Fibrosis: A Multinational European Survey","volume":"8","author":"van der Sar","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2025083110035431000_11.1.e002368.21","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/resp.14154","article-title":"Idiopathic pulmonary fibrosis: Physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden","volume":"27","author":"Lancaster","year":"2022","journal-title":"Respirology"},{"key":"2025083110035431000_11.1.e002368.22","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-019-1228-2","article-title":"Diagnostic test interpretation and referral delay in patients with interstitial lung disease","volume":"20","author":"Pritchard","year":"2019","journal-title":"Respir Res"},{"key":"2025083110035431000_11.1.e002368.23","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1164\/rccm.202110-2296OC","article-title":"The Proteomic Profile of Interstitial Lung Abnormalities","volume":"206","author":"Axelsson","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2025083110035431000_11.1.e002368.24","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2021204367"},{"key":"2025083110035431000_11.1.e002368.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2020.104025"},{"key":"2025083110035431000_11.1.e002368.26","doi-asserted-by":"crossref","first-page":"15620","DOI":"10.1038\/s41598-020-72607-1","article-title":"Antifibrotic treatment improves clinical outcomes in patients with idiopathic pulmonary fibrosis: a propensity score matching analysis","volume":"10","author":"Kang","year":"2020","journal-title":"Sci Rep"},{"key":"2025083110035431000_11.1.e002368.27","unstructured":"NICE . Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted. 2023."},{"key":"2025083110035431000_11.1.e002368.28","unstructured":"NICE . Nintedanib for treating progressive fibrosing interstitial lung diseases. 2021."},{"key":"2025083110035431000_11.1.e002368.29","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-021-01595-3","article-title":"Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis","volume":"21","author":"Sugino","year":"2021","journal-title":"BMC Pulm Med"},{"key":"2025083110035431000_11.1.e002368.30","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s41030-023-00216-0","article-title":"Early Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis: A Narrative Review","volume":"9","author":"Alsomali","year":"2023","journal-title":"Pulm Ther"},{"key":"2025083110035431000_11.1.e002368.31","doi-asserted-by":"crossref","first-page":"102149","DOI":"10.1016\/j.pupt.2022.102149","article-title":"Real-world safety profiles of pirfenidone and nintedanib in idiopathic pulmonary fibrosis patients","volume":"76","author":"Fournier","year":"2022","journal-title":"Pulm Pharmacol Ther"},{"key":"2025083110035431000_11.1.e002368.32","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-020-01458-1","article-title":"Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study","volume":"21","author":"Moor","year":"2020","journal-title":"Respir Res"},{"key":"2025083110035431000_11.1.e002368.33","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00408-019-00260-1","article-title":"Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients","volume":"197","author":"Proesmans","year":"2019","journal-title":"Lung"},{"key":"2025083110035431000_11.1.e002368.34","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0125-2019","article-title":"The supportive care needs of people living with pulmonary fibrosis and their caregivers: a systematic review","volume":"29","author":"Lee","year":"2020","journal-title":"Eur Respir Rev"},{"key":"2025083110035431000_11.1.e002368.35","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0080-2016","article-title":"Oxygen therapy for interstitial lung disease: a systematic review","volume":"26","author":"Bell","year":"2017","journal-title":"Eur Respir Rev"},{"key":"2025083110035431000_11.1.e002368.36","article-title":"Pulmonary rehabilitation for interstitial lung disease","volume":"2021","author":"Dowman","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2025083110035431000_11.1.e002368.37","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S2213-2600(18)30289-3","article-title":"Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial","volume":"6","author":"Visca","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2025083110035431000_11.1.e002368.38","doi-asserted-by":"crossref","unstructured":"Mann JMV , Holland AE , Goh NSL , et al . Understanding patient experience of chronic cough in interstitial lung disease. ERJ Open Res 2023;9. doi:10.1183\/23120541.00039-2023","DOI":"10.1183\/23120541.00039-2023"},{"key":"2025083110035431000_11.1.e002368.39","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-216244"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2024-002368","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T17:04:06Z","timestamp":1756659846000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2024-002368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,9,3]]},"published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1136\/bmjresp-2024-002368"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2024-002368","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9]]}}}